The Role of Chromosome 8p22 Deletion for Predicting Disease Progression and Pathological Staging in Prostate Cancer

Abstract

The natural course of human prostate cancer is highly variable, and we still lack reliable tools to predict the patient's outcome. Recent publications suggest that the deletion of chromosome 8p22 has an important role for tumor progression in prostate cancer. Totally, 97 patients (41 Japanese and 56 Swedish) were studied to detect the status of chromosome 8p22 deletion by the fluorescence in situ hybridization (FISH) technique. Seventy-seven underwent surgery (59 radical prostatectomies or 18 lymph node dissections), and the specimens were prepared by touch biopsy. Fine-needle aspiration biopsies (FNAB) were obtained from another non-operative 20 cases. Disease progression was evaluated in 57 patients with a median follow-up of 59 months. 8p22 deletions were detected in 58 (60 %) of all cases. The frequency of 8p22 deletion did not significantly differ between different preparations of specimens (touch biopsy vs. FNAB) as well as between different races (Japanese vs. Swedish). Cases with more than pT3 tumors had a significantly higher frequency of 8p22 deletion than those with pT2 (p < 0.01). Multivariate analysis demonstrated that 8p22 deletion was the strongest parameter to predict disease progression (hazard ratio = 5.75; p = 0.0001). Studies on chromosomal deletions of 8p22 by the FISH technique may serve as a universal genetic marker to optimize the treatment strategy in patients with prostate cancer.

Key words

FISH - prostate cancer - disease progression

References

• 1 Chev M, Lewis P, Banerjee M, Hurley P, Sakr W, Grignon D, Powell I. A similar pattern of chromosomal alterations in prostate cancers from African-Americans and Caucasian-Americans.  Clin Cancer Res. 1988;  4 1273-1278
• 2 Trapasso J, deKernion J, Smith R, Dorey F. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.  J Urol. 1994;  152 1821-1825
• 3 Sato K, Qian J, Slezak J M, Lieber M M, Bostwick D G, Bergstrahl E J, Jenkins R B. Clinical significance of alterations of chromosome 8 in high-grade, advanced, nonmetastatic prostate carcinoma.  J Natl Cancer Inst. 1999;  91 1574-1580
• 4 Matsuyama H, Pan Y, Skoog L, Tribukait B, Naito K, Ekman P, Lichter P, Bergerheim U S. Deletion mapping of chromosome 8p in prostate cancer by fluorescence in situ hybridization.  Oncogene. 1994;  9 3071-3076
• 5 Pan Y, Matsuyama H, Wang N, Yoshihiro S, Haggarth L, Li C, Tribukait B, Ekman P, Bergerheim U. Chromosome 16q24 deletion and decreased E-cadherin expression: possible association with metastatic potential in prostate cancer.  Prostate. 1998;  36 31-38
• 6 Schellhammer P, el-Mahdi A, Kuban D, Wright G J. Prostate-specific antigen after radiation therapy. Prognosis by pretreatment level and post-treatment nadir.  Urol Clin North Am. 1997;  24 407-414
• 7 Matsuyama H, Bergerheim U SR, Nilsson I, Pan Y, Skoog L, Tribukait B, Ekman P. Non-random numerical aberrations of chromosomes 7, 9 and 10 in DNA-diploid bladder cancer.  Cancer Genet Cytogenet. 1994;  77 118-124
• 8 Oba K, Matsuyama H, Yoshihiro S, Kishi F, Takahashi M, Tsukamoto M, Kinjo M, Sagiyama K, Naito K. Two putative tumor suppressor genes on chromosome arm 8p may play different roles in prostate cancer.  Cancer Genet Cytogenet. 2001;  124 20-26
• 9 Cabeza A Y, Sepulveda J L, Lebovitz R M, Thompson T C, Chinault A C. Functional identification of LZTS 1 as a candidate prostate tumor suppressor gene on human chromosome 8p22.  Oncogene. 2001;  20 4169-4179